Rosa P Gomariz Selected Research

Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))

1/2020	Vasoactive intestinal peptide axis is dysfunctional in patients with Graves' disease.
1/2018	Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.
1/2018	The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis.
12/2016	VIP impairs acquisition of the macrophage proinflammatory polarization profile.
1/2016	Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity.
8/2015	Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect.
7/2015	Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity.
1/2014	VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction.
1/2014	Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis.
1/2014	Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rosa P Gomariz Research Topics

Disease

13	Rheumatoid Arthritis 01/2020 - 01/2005
10	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 01/2002
10	Inflammation (Inflammations) 08/2019 - 05/2003
9	Arthritis (Polyarthritis) 12/2021 - 05/2003
9	Osteoarthritis 06/2021 - 06/2011
5	Crohn Disease (Crohn's Disease) 06/2008 - 04/2003
5	Septic Shock (Toxic Shock Syndrome) 07/2006 - 01/2002
4	Experimental Arthritis 01/2018 - 01/2005
3	Rheumatic Diseases (Rheumatism) 08/2019 - 01/2013
3	Colitis 08/2005 - 04/2003
2	Infections 01/2020 - 01/2018
2	Neoplasms (Cancer) 01/2016 - 09/2010
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2013 - 05/2003
2	Multiple Sclerosis 01/2006 - 05/2003
1	Bone Resorption 12/2021
1	Graves Disease (Basedow Disease) 01/2020
1	Joint Diseases (Joint Disease) 08/2019
1	Synovitis 07/2017
1	Knee Osteoarthritis 07/2017
1	Pain (Aches) 07/2017
1	Pathologic Processes 01/2016
1	Disease Progression 01/2016
1	Edema (Dropsy) 07/2015
1	Back Pain (Backache) 07/2015
1	Ankylosing Spondylitis 07/2015
1	Melanoma (Melanoma, Malignant) 06/2011
1	Neoplasm Metastasis (Metastasis) 09/2010
1	Breast Neoplasms (Breast Cancer) 09/2010
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 02/2009

Drug/Important Bio-Agent (IBA)

18	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 01/2020 - 04/2003
10	CytokinesIBA 01/2020 - 01/2002
5	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 02/2009 - 01/2002
4	ChemokinesIBA 01/2020 - 04/2003
4	Peptides (Polypeptides)IBA 02/2009 - 08/2005
3	NeuropeptidesIBA 12/2021 - 01/2002
3	Fibronectins (Fibronectin)IBA 12/2019 - 01/2014
3	Metalloproteases (Metalloproteinases)IBA 01/2019 - 01/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2016 - 01/2002
3	LipopolysaccharidesIBA 01/2013 - 01/2002
3	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2013 - 08/2005
3	Type I Pituitary Adenylate Cyclase-Activating Polypeptide ReceptorsIBA 07/2006 - 01/2002
2	Peptide Hydrolases (Proteases)FDA Link 12/2021 - 12/2019
2	Proteins (Proteins, Gene)FDA Link 06/2021 - 08/2005
2	Biomarkers (Surrogate Marker)IBA 12/2020 - 01/2014
2	LigandsIBA 01/2020 - 01/2013
2	Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)IBA 01/2020 - 01/2016
2	Growth Hormone (Somatotropin)IBA 01/2018 - 11/2013
2	DisintegrinsIBA 04/2016 - 01/2016
2	Aggrecans (Aggrecan)IBA 04/2016 - 01/2016
2	ThrombospondinsIBA 04/2016 - 01/2016
2	CateninsIBA 01/2016 - 09/2010
2	Interleukin-22 (IL-22)IBA 01/2014 - 12/2013
2	Fibrinogen (Factor I)FDA Link 07/2006 - 05/2005
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 07/2006 - 05/2005
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 07/2006 - 05/2005
2	Sulfonic AcidsIBA 08/2005 - 04/2003
2	Therapeutic UsesIBA 05/2005 - 04/2003
1	Messenger RNA (mRNA)IBA 01/2020
1	Antirheumatic Agents (DMARD)IBA 01/2020
1	Methotrexate (Mexate)FDA LinkGeneric 01/2020
1	Rituximab (Mabthera)FDA Link 01/2020
1	ProgranulinsIBA 08/2019
1	LeptinIBA 08/2019
1	AdiponectinIBA 08/2019
1	ResistinIBA 08/2019
1	AdipokinesIBA 08/2019
1	Nicotinamide PhosphoribosyltransferaseIBA 08/2019
1	Lipocalin-2IBA 08/2019
1	Biological ProductsIBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2018
1	AutoantigensIBA 01/2018
1	Chondroitin Sulfates (Chondroitin Sulfate)IBA 07/2017
1	ChondroitinIBA 07/2017
1	Cartilage Oligomeric Matrix ProteinIBA 01/2016
1	Type I Vasoactive Intestinal Polypeptide ReceptorsIBA 01/2016
1	Hemoglobins (Hemoglobin)IBA 07/2015
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2014
1	Corticotropin-Releasing HormoneIBA 01/2014
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2014
1	AlarminsIBA 12/2013
1	Insulin (Novolin)FDA Link 11/2013
1	Poly I-CIBA 01/2013
1	Interleukin-12 (IL 12)IBA 01/2013
1	Interleukin-17 ReceptorsIBA 01/2013
1	Interleukin-23 (Interleukin 23)IBA 01/2013
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2013
1	UrocortinsIBA 12/2011
1	RNA (Ribonucleic Acid)IBA 06/2011
1	Matrix Metalloproteinase 3 (Stromelysin 1)IBA 06/2011
1	InterferonsIBA 06/2011
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 06/2011
1	Toll-Like Receptor 3IBA 06/2011
1	Antiviral Agents (Antivirals)IBA 06/2011
1	Transcription Factors (Transcription Factor)IBA 06/2011
1	Double-Stranded RNA (RNA, Double Stranded)IBA 06/2011
1	Interleukin-8 (Interleukin 8)IBA 06/2011
1	antalarminIBA 09/2010

Therapy/Procedure

9	Therapeutics 12/2019 - 01/2002
2	Critical Care (Surgical Intensive Care) 07/2006 - 05/2005
1	Immunomodulation 01/2013